ReviewNature reviews. Neurology2026
The potential of low-field MRI for global dementia care.
Review in Nature reviews. Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advancing the Volumetric Analysis of Ultra-Low-Field Brain MRI Using Image-to-Image Translation.Magnetic resonance in medicine · 2026Article
- Reply to 'Low-field MRI for equitable epilepsy diagnosis in resource-limited settings'.Nature reviews. Neurology · 2026Article
- Low-field MRI for equitable epilepsy diagnosis in resource-limited settings.Nature reviews. Neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With elderly populations increasing in many countries, rates of Alzheimer disease and related dementias (ADRD) are expected to rise worldwide in the coming years. Low-income and middle-income countries, where barriers to health care are most pronounced and research representation is limited, are predicted to experience the greatest increases in ADRD prevalence. Access to advanced diagnostic and research tools, such as neuroimaging, is severely restricted in these regions, but low-field MRI is emerging as a promising, accessible alternative to conventional imaging. By reducing infrastructure, cost and siting requirements, low-field MRI offers a potential pathway to expand access to dementia-relevant imaging beyond specialized centres. In this article, we summarize key structural imaging biomarkers in ADRD and review the current literature supporting the use of low-field MRI in the ADRD field. We highlight the utility of low-field MRI for the assessment of regional atrophy and cerebrovascular lesion burden and discuss emerging diffusion-based markers. We also consider challenges and future directions, offering insights to advance equitable access to diagnostic imaging, guide research priorities and support global implementation of low-field MRI in ADRD care and investigation.
Indexed as
Identifiers
41946975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.